Attachment II - Ffege 3 
9202-015 
(M/PB/TIL) 
Economou, James S. and Belldegrun, Arie; University of California at Los Angeles, Los Angeles, 
California; The Treatment of Patients with Metastatic Melanoma and Renal Cell Cancer Using In Vitro 
Expanded and Genetically-Engineered (Neomycin Phosphotransferase) Bulk, CD8 ( + ) and/or CD4( + ) 
Tumor Infiltrating Lymphocytes and Bulk, CD8( + ) and/or CD4( + ) Peripheral Blood Leukocytes in 
Combination with Recombinant Interleukin-2 Alone, or with Recombinant Interleukin-2 and 
Recombinant Alpha Interferon. 
RAC Approval: 2-11-92/NIH Approval: 4-17-92 
CLOSED: 6-94 
9202-016 3 
(T/V/C/Ovarian) 
Freeman, Scott M.; Tulane University Medical Center, New Orleans, Louisiana; Gene Transfer for 
the Treatment of Cancer. 
RAC Approval: 2-10-92/NIH Approval: 2-5-93 
Minor Modification: 8-6-93 
9202-017 b 
(M/CTL) 
Greenberg, Philip D. and Riddell, Stanley, Fred Hutchinson Cancer Research Center, University of 
Washington, Seattle; Phase I Study to Evaluate the Safety of Cellular Adoptive Immunotherapy using 
Genetically Modified CD8+ HIV-Specific T Cells in HIV Seropositive Individuals. 
RAC Approval: 2-11-92/NIH Approval: 4-17-92 
Major Amendment/RAC Approval: . 9-9-93 
Major Amendment/NIH Approval: 10-7-93 
9206-018 3 
(T/V/C/Neuroblastoma) 
Brenner, Malcolm K.; Furman, Wayne; Santana, Victor; Bowman, Laura; and Meyer, William; St. 
Jude Children’s Research Hospital, Memphis, Tennessee; Phase I Study of Cytokine-Gene Modified 
Autologous Neuroblastoma Cells for Treatment of Relapsed/Refractory Neuroblastoma. 
RAC Approval: 6-1-92/NIH Approval: 8-14-92 
Minor Modification: 6-23-94 
9206-019 3 
(T/C/Brain) 
Oldfield, Edward; National Institutes of Health, Bethesda, Maryland; Gene Therapy for the Treatment 
of Brain Tumors Using Intra-Tumoral Transduction with the Thymidine Kinase Gene and Intravenous 
Ganciclovir. 
RAC Approval: 6-1-92/NIH Approval: 8-14-92 
Minor Modification: 11-29-93 
9206-020 3 
(M/BM/PB) 
Deisseroth, Albert B.; MD Anderson Cancer Center, Houston, Texas; Use of Two Retroviral Markers 
to Test Relative Contribution of Marrow and Peripheral Blood Autologous Cells to Recovery After 
Preparative Therapy. 
RAC Approval: 6-2-92/NIH Approval: 8-14-92 
Minor Modification: 4-19-93 
9206-021 
(T/V/C/Melanoma) 
Gansbacher, Bernd; Houghton, Alan; and Livingston, Philip; Memorial Sloan Kettering Cancer 
Center, New York, New York; Immunization with HLA-A2 matched Allogeneic Melanoma Cells that 
Secrete Interleukin-2 in Patients with Metastatic Melanoma. 
RAC Approval: 6-2-92/NIH Approval: 8-14-92 
CLOSED: 10-19-94 
Recombinant DNA Research, Volume 20 
[491] 
